These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

493 related items for PubMed ID: 24389101

  • 1. Targeting MLL1 H3K4 methyltransferase activity in mixed-lineage leukemia.
    Cao F, Townsend EC, Karatas H, Xu J, Li L, Lee S, Liu L, Chen Y, Ouillette P, Zhu J, Hess JL, Atadja P, Lei M, Qin ZS, Malek S, Wang S, Dou Y.
    Mol Cell; 2014 Jan 23; 53(2):247-61. PubMed ID: 24389101
    [Abstract] [Full Text] [Related]

  • 2. High-affinity small molecular blockers of mixed lineage leukemia 1 (MLL1)-WDR5 interaction inhibit MLL1 complex H3K4 methyltransferase activity.
    Li DD, Chen WL, Wang ZH, Xie YY, Xu XL, Jiang ZY, Zhang XJ, You QD, Guo XK.
    Eur J Med Chem; 2016 Nov 29; 124():480-489. PubMed ID: 27598236
    [Abstract] [Full Text] [Related]

  • 3. Proton pump inhibitors selectively suppress MLL rearranged leukemia cells via disrupting MLL1-WDR5 protein-protein interaction.
    Chen WL, Li DD, Chen X, Wang YZ, Xu JJ, Jiang ZY, You QD, Guo XK.
    Eur J Med Chem; 2020 Feb 15; 188():112027. PubMed ID: 31923859
    [Abstract] [Full Text] [Related]

  • 4. Piribedil disrupts the MLL1-WDR5 interaction and sensitizes MLL-rearranged acute myeloid leukemia (AML) to doxorubicin-induced apoptosis.
    Zhang X, Zheng X, Yang H, Yan J, Fu X, Wei R, Xu X, Zhang Z, Yu A, Zhou K, Ding J, Geng M, Huang X.
    Cancer Lett; 2018 Sep 01; 431():150-160. PubMed ID: 29857126
    [Abstract] [Full Text] [Related]

  • 5. On the mechanism of multiple lysine methylation by the human mixed lineage leukemia protein-1 (MLL1) core complex.
    Patel A, Dharmarajan V, Vought VE, Cosgrove MS.
    J Biol Chem; 2009 Sep 04; 284(36):24242-56. PubMed ID: 19556245
    [Abstract] [Full Text] [Related]

  • 6. Automethylation activities within the mixed lineage leukemia-1 (MLL1) core complex reveal evidence supporting a "two-active site" model for multiple histone H3 lysine 4 methylation.
    Patel A, Vought VE, Swatkoski S, Viggiano S, Howard B, Dharmarajan V, Monteith KE, Kupakuwana G, Namitz KE, Shinsky SA, Cotter RJ, Cosgrove MS.
    J Biol Chem; 2014 Jan 10; 289(2):868-84. PubMed ID: 24235145
    [Abstract] [Full Text] [Related]

  • 7. Structural basis for WDR5 interaction (Win) motif recognition in human SET1 family histone methyltransferases.
    Dharmarajan V, Lee JH, Patel A, Skalnik DG, Cosgrove MS.
    J Biol Chem; 2012 Aug 10; 287(33):27275-89. PubMed ID: 22665483
    [Abstract] [Full Text] [Related]

  • 8. Targeted Disruption of the Interaction between WD-40 Repeat Protein 5 (WDR5) and Mixed Lineage Leukemia (MLL)/SET1 Family Proteins Specifically Inhibits MLL1 and SETd1A Methyltransferase Complexes.
    Alicea-Velázquez NL, Shinsky SA, Loh DM, Lee JH, Skalnik DG, Cosgrove MS.
    J Biol Chem; 2016 Oct 21; 291(43):22357-22372. PubMed ID: 27563068
    [Abstract] [Full Text] [Related]

  • 9. Structure-based design of ester compounds to inhibit MLL complex catalytic activity by targeting mixed lineage leukemia 1 (MLL1)-WDR5 interaction.
    Li DD, Wang ZH, Chen WL, Xie YY, You QD, Guo XK.
    Bioorg Med Chem; 2016 Nov 15; 24(22):6109-6118. PubMed ID: 27720555
    [Abstract] [Full Text] [Related]

  • 10. Histone methyltransferase MLL1 regulates MDR1 transcription and chemoresistance.
    Huo H, Magro PG, Pietsch EC, Patel BB, Scotto KW.
    Cancer Res; 2010 Nov 01; 70(21):8726-35. PubMed ID: 20861184
    [Abstract] [Full Text] [Related]

  • 11. The Development of Inhibitors Targeting the Mixed Lineage Leukemia 1 (MLL1)-WD Repeat Domain 5 Protein (WDR5) Protein- Protein Interaction.
    Ye X, Chen G, Jin J, Zhang B, Wang Y, Cai Z, Ye F.
    Curr Med Chem; 2020 Nov 01; 27(33):5530-5542. PubMed ID: 31132972
    [Abstract] [Full Text] [Related]

  • 12. Structural basis of nucleosome recognition and modification by MLL methyltransferases.
    Xue H, Yao T, Cao M, Zhu G, Li Y, Yuan G, Chen Y, Lei M, Huang J.
    Nature; 2019 Sep 01; 573(7774):445-449. PubMed ID: 31485071
    [Abstract] [Full Text] [Related]

  • 13. Regulation of MLL1 H3K4 methyltransferase activity by its core components.
    Dou Y, Milne TA, Ruthenburg AJ, Lee S, Lee JW, Verdine GL, Allis CD, Roeder RG.
    Nat Struct Mol Biol; 2006 Aug 01; 13(8):713-9. PubMed ID: 16878130
    [Abstract] [Full Text] [Related]

  • 14. Analysis of the binding of mixed lineage leukemia 1 (MLL1) and histone 3 peptides to WD repeat domain 5 (WDR5) for the design of inhibitors of the MLL1-WDR5 interaction.
    Karatas H, Townsend EC, Bernard D, Dou Y, Wang S.
    J Med Chem; 2010 Jul 22; 53(14):5179-85. PubMed ID: 20575550
    [Abstract] [Full Text] [Related]

  • 15. High-affinity, small-molecule peptidomimetic inhibitors of MLL1/WDR5 protein-protein interaction.
    Karatas H, Townsend EC, Cao F, Chen Y, Bernard D, Liu L, Lei M, Dou Y, Wang S.
    J Am Chem Soc; 2013 Jan 16; 135(2):669-82. PubMed ID: 23210835
    [Abstract] [Full Text] [Related]

  • 16. Discovery of DDO-2213 as a Potent and Orally Bioavailable Inhibitor of the WDR5-Mixed Lineage Leukemia 1 Protein-Protein Interaction for the Treatment of MLL Fusion Leukemia.
    Chen W, Chen X, Li D, Zhou J, Jiang Z, You Q, Guo X.
    J Med Chem; 2021 Jun 24; 64(12):8221-8245. PubMed ID: 34105966
    [Abstract] [Full Text] [Related]

  • 17. Inhibition of the H3K4 methyltransferase MLL1/WDR5 complex attenuates renal senescence in ischemia reperfusion mice by reduction of p16INK4a.
    Shimoda H, Doi S, Nakashima A, Sasaki K, Doi T, Masaki T.
    Kidney Int; 2019 Nov 24; 96(5):1162-1175. PubMed ID: 31570196
    [Abstract] [Full Text] [Related]

  • 18. Hematopoietic transformation in the absence of MLL1/KMT2A: distinctions in target gene reactivation.
    Chen Y, Ernst P.
    Cell Cycle; 2019 Jul 24; 18(14):1525-1531. PubMed ID: 31161857
    [Abstract] [Full Text] [Related]

  • 19. Discovery of a potent MLL1 and WDR5 protein-protein interaction inhibitor with in vivo antitumor activity.
    Chen W, Chen X, Li D, Wang X, Long G, Jiang Z, You Q, Guo X.
    Eur J Med Chem; 2021 Nov 05; 223():113677. PubMed ID: 34225179
    [Abstract] [Full Text] [Related]

  • 20. Targeting human SET1/MLL family of proteins.
    Vedadi M, Blazer L, Eram MS, Barsyte-Lovejoy D, Arrowsmith CH, Hajian T.
    Protein Sci; 2017 Apr 05; 26(4):662-676. PubMed ID: 28160335
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.